Lucilla Piccari
YOU?
Author Swipe
View article: Effects of pulmonary arterial hypertension therapies on arterial oxygenation in patients with pulmonary hypertension associated with lung disease: a systematic review and meta-analysis
Effects of pulmonary arterial hypertension therapies on arterial oxygenation in patients with pulmonary hypertension associated with lung disease: a systematic review and meta-analysis Open
Background Pulmonary hypertension (PH) associated with lung disease entails a poor prognosis. There is concern about the potential deleterious effect on gas exchange of drugs approved for pulmonary arterial hypertension (PAH) in patients w…
View article: Significance of Pulmonary Vascular Dysfunction in Chronic Obstructive Pulmonary Disease
Significance of Pulmonary Vascular Dysfunction in Chronic Obstructive Pulmonary Disease Open
Chronic obstructive pulmonary disease (COPD) is frequently accompanied by abnormalities of the pulmonary vasculature. This vasculopathy spans the spectrum from mild vascular dysfunction to pulmonary hypertension, which on rare occasions ca…
View article: Cardiopulmonary Exercise Testing With Simultaneous Echocardiography After Pulmonary Embolism
Cardiopulmonary Exercise Testing With Simultaneous Echocardiography After Pulmonary Embolism Open
Although current guidelines recommend standard cardiopulmonary exercise testing (CPET) to evaluate symptomatic patients after pulmonary embolism (PE), CPET with simultaneous echocardiography could provide relevant information to evaluate r…
View article: Pathology of idiopathic pulmonary fibrosis with particular focus on vascular endothelium and epithelial injury and their therapeutic potential
Pathology of idiopathic pulmonary fibrosis with particular focus on vascular endothelium and epithelial injury and their therapeutic potential Open
Idiopathic pulmonary fibrosis (IPF) remains a challenging disease with no drugs available to change the trajectory. It is a condition associated with excessive and highly progressive scarring of the lungs with remodelling and extracellular…
View article: Screening and diagnosis of pulmonary hypertension associated with chronic lung disease (PH‐CLD): A consensus statement from the pulmonary vascular research institute's innovative drug development initiative—group 3 pulmonary hypertension
Screening and diagnosis of pulmonary hypertension associated with chronic lung disease (PH‐CLD): A consensus statement from the pulmonary vascular research institute's innovative drug development initiative—group 3 pulmonary hypertension Open
Pulmonary hypertension (PH) is a frequent complication of chronic lung disease (CLD). However, PH is difficult to diagnose early since accompanying symptoms overlap and are similar to those of the underlying CLD. In most cases the PH is mi…
View article: Use of non-invasive mechanical ventilation in the Emergency Department, clinical outcomes and correlates of failure
Use of non-invasive mechanical ventilation in the Emergency Department, clinical outcomes and correlates of failure Open
Background: Despite several studies having been carried in this organizational context, there is an absence of information about the effectiveness of non-invasive mechanical ventilation (NIV) in Emergency Departments (ED), based on a numbe…
View article: Pulmonary vascular disease, environmental pollution, and climate change
Pulmonary vascular disease, environmental pollution, and climate change Open
Pollution and climate change constitute a combined, grave and pervasive threat to humans and to the life‐support systems on which they depend. Evidence shows a strong association between pollution and climate change on cardiovascular and r…
View article: The European Voice of the Patient living with pulmonary hypertension associated with interstitial lung disease: Diagnosis, symptoms, impacts, and treatments
The European Voice of the Patient living with pulmonary hypertension associated with interstitial lung disease: Diagnosis, symptoms, impacts, and treatments Open
Pulmonary hypertension (PH) adds a substantial disease burden, including higher mortality, when associated with interstitial lung disease (ILD), a severe, chronic, progressive condition. Yet little is known of the lived experiences, perspe…
View article: Adaptive multi-interventional trial platform to improve patient care for fibrotic interstitial lung diseases
Adaptive multi-interventional trial platform to improve patient care for fibrotic interstitial lung diseases Open
Background Fibrotic interstitial lung diseases (fILDs) are a heterogeneous group of lung diseases associated with significant morbidity and mortality. Despite a large increase in the number of clinical trials in the last 10 years, current …
View article: Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension
Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension Open
Pulmonary hypertension (PH) due to interstitial lung disease (ILD), a commonly encountered complication of fibrotic ILDs, is associated with significant morbidity and mortality. Until recently, the studies of pulmonary vasodilator therapy …
View article: Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism in SARS-CoV-2
Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism in SARS-CoV-2 Open
Introduction: Chronic thromboembolic pulmonary disease (CTEPD) consists of persistent pulmonary vascular obstruction on imaging and involves long-term functional limitations, with or without chronic thromboembolic pulmonary hypertension (C…
View article: ERS International Congress 2023: highlights from the Pulmonary Vascular Diseases Assembly
ERS International Congress 2023: highlights from the Pulmonary Vascular Diseases Assembly Open
Pulmonary vascular diseases such as pulmonary embolism and pulmonary hypertension are important and frequently under-recognised conditions. This article provides an overview of key highlights in pulmonary vascular diseases from the Europea…
View article: Fossil Industry and Respiratory Societies: Time for a Clear Stand
Fossil Industry and Respiratory Societies: Time for a Clear Stand Open
"Fossil Industry and Respiratory Societies – Time for a Clear Stand." American Journal of Respiratory and Critical Care Medicine, 0(ja), pp.
View article: Mechanisms of hypoxaemia in severe pulmonary hypertension associated with COPD
Mechanisms of hypoxaemia in severe pulmonary hypertension associated with COPD Open
Severe hypoxaemia, characteristic of COPD with severe pulmonary hypertension, is due to a combination of greater ventilation–perfusion mismatch, increased intrapulmonary shunt and reduced P(vO(2)), with negligible hypoxic pulmonary vasocon…
View article: Effects of Exercise Training on Circulating Biomarkers of Endothelial Function in Pulmonary Arterial Hypertension
Effects of Exercise Training on Circulating Biomarkers of Endothelial Function in Pulmonary Arterial Hypertension Open
Introduction: In stable patients with pulmonary arterial hypertension (PAH), pulmonary rehabilitation (PR) is an effective, safe and cost-effective non-pharmacological treatment. However, the effects of PR on vascular function have been po…
View article: Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative ‐ Group 3 Pulmonary Hypertension
Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative ‐ Group 3 Pulmonary Hypertension Open
Pulmonary hypertension (PH) is a frequent complication of interstitial lung disease (ILD). Although PH has mostly been described in idiopathic pulmonary fibrosis, it can manifest in association with many other forms of ILD. Associated path…
View article: Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension
Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension Open
Pulmonary hypertension (PH) associated with interstitial lung disease (ILD) is an attractive target for clinical trials of PH medications. There are many factors that need to be considered to prime such studies for success. The patient phe…
View article: Emerging phenotypes of pulmonary hypertension associated with COPD: a field guide
Emerging phenotypes of pulmonary hypertension associated with COPD: a field guide Open
Purpose of review Pulmonary hypertension (PH) is a common complication of chronic obstructive lung disease (COPD), but clinical presentation is variable and not always ’proportional’ to the severity of the obstructive disease. This review …
View article: Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative—Group 3 pulmonary hypertension
Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative—Group 3 pulmonary hypertension Open
Pulmonary hypertension (PH) has been linked to worse outcomes in chronic lung diseases. The presence of PH in the setting of underlying Interstitial Lung Disease (ILD) is strongly associated with decreased exercise and functional capacity,…
View article: ERS International Congress 2021: highlights from the Pulmonary Vascular Diseases Assembly
ERS International Congress 2021: highlights from the Pulmonary Vascular Diseases Assembly Open
This article aims to summarise the latest research presented at the virtual 2021 European Respiratory Society (ERS) International Congress in the field of pulmonary vascular disease. In light of the current guidelines and proceedings, know…
View article: Supplementary Material for: The Effect of Borderline Pulmonary Hypertension on Survival in Chronic Lung Disease
Supplementary Material for: The Effect of Borderline Pulmonary Hypertension on Survival in Chronic Lung Disease Open
Background: The impact of the new “borderline” hemodynamic class for pulmonary hypertension (PH) (mean pulmonary artery pressure [mPAP], 21–24 mm Hg and pulmonary vascular resistance, [PVR], ≥3 wood units, [WU]) in chronic obstructive pulm…
View article: The Effect of Borderline Pulmonary Hypertension on Survival in Chronic Lung Disease
The Effect of Borderline Pulmonary Hypertension on Survival in Chronic Lung Disease Open
Background: The impact of the new “borderline” hemodynamic class for pulmonary hypertension (PH) (mean pulmonary artery pressure [mPAP], 21–24 mm Hg and pulmonary vascular resistance, [PVR], ≥3 wood units, [WU]) in chronic obstructive pulm…
View article: Metabolic Profile in Endothelial Cells of Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension.
Metabolic Profile in Endothelial Cells of Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension. Open
Background Chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) are two forms of pulmonary hypertension (PH) characterized by obstructive vasculopathy. Endothelial dysfunction along with metabolic…
View article: Iron Replacement and Redox Balance in Non-Anemic and Mildly Anemic Iron Deficiency COPD Patients: Insights from a Clinical Trial
Iron Replacement and Redox Balance in Non-Anemic and Mildly Anemic Iron Deficiency COPD Patients: Insights from a Clinical Trial Open
In COPD patients, non-anemic iron deficiency (NAID) is a common systemic manifestation. We hypothesized that in COPD patients with NAID, iron therapy may improve systemic oxidative stress. The FACE (Ferinject assessment in patients with CO…
View article: Derivation and Characterisation of Endothelial Cells from Patients with Chronic Thromboembolic Pulmonary Hypertension.
Derivation and Characterisation of Endothelial Cells from Patients with Chronic Thromboembolic Pulmonary Hypertension. Open
Rationale: Pulmonary endarterectomy (PEA) resected material offers a unique opportunity to develop an in vitro endothelial cell model of chronic thromboembolic pulmonary hypertension (CTEPH). We aimed to comprehensively analyze the endothe…